Baker BROS. Advisors LP Grows Stake in Enliven Therapeutics, Inc. $ELVN

Baker BROS. Advisors LP grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 136.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 271,406 shares of the company’s stock after buying an additional 156,573 shares during the period. Baker BROS. Advisors LP owned 0.46% of Enliven Therapeutics worth $4,180,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares in the last quarter. BNP Paribas Financial Markets increased its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares in the last quarter. Quantbot Technologies LP increased its position in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after buying an additional 3,490 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics during the fourth quarter worth $83,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Insiders Place Their Bets

In related news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the transaction, the director owned 51,884 shares in the company, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on ELVN shares. HC Wainwright raised their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. The Goldman Sachs Group raised their price target on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Stifel Nicolaus started coverage on Enliven Therapeutics in a research report on Tuesday, June 9th. They set a “buy” rating and a $60.00 price target for the company. Finally, Guggenheim assumed coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $63.40.

Enliven Therapeutics Trading Up 5.4%

Shares of Enliven Therapeutics stock opened at $44.86 on Thursday. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $48.53. The stock has a market capitalization of $2.73 billion, a P/E ratio of -26.86 and a beta of 0.29. The business’s fifty day moving average price is $41.73 and its 200 day moving average price is $31.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.71 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.